APA (7th ed.) Citation

Avery, R., Diack, C., Holekamp, N., Lhor, M., Mar, F., & Maass, K. (2026). Ocular Half-Life: What it Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability. Ophthalmology & Therapy, 15(4), 1195. https://doi.org/10.1007/s40123-026-01358-5

Chicago Style (17th ed.) Citation

Avery, Robert, Cheikh Diack, Nancy Holekamp, Mustapha Lhor, Florie Mar, and Katie Maass. "Ocular Half-Life: What It Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability." Ophthalmology & Therapy 15, no. 4 (2026): 1195. https://doi.org/10.1007/s40123-026-01358-5.

MLA (9th ed.) Citation

Avery, Robert, et al. "Ocular Half-Life: What It Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability." Ophthalmology & Therapy, vol. 15, no. 4, 2026, p. 1195, https://doi.org/10.1007/s40123-026-01358-5.